Navigation Links
Neurobiological Technologies Sets Date for Third Quarter Financial Results
Date:5/8/2008

EMERYVILLE, Calif., May 8 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it will release its third quarter 2008 financial results, for the quarter ended March 31, 2008, on May 12, 2008 and host a conference call on May 13, 2008.

Hosting the call will be Paul E. Freiman, President and Chief Executive Officer, and Matthew M. Loar, Vice President and Chief Financial Officer. The details for the call are as follows:

-- Date: Tuesday, May 13, 2008

-- Time: 10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT

-- Dial-in number: 877-591-4953 U.S. / 719-325-4851 International

Web cast of call: A live web cast can be accessed online by going to:

http://investor.shareholder.com/ntii/events.cfm

The call will be archived and accessible at the same website for 90 days

Telephonic Replay: A playback of the conference call will be available

from 1:30 pm (ET) on May 13, 2008 to midnight on May 17, 2008. Reply

number:

888-203-1112 U.S. / 719-457-0820 International Pass code: 3838724

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug with multiple mechanisms of action that is specifically designed to double the time period that patients can be treated after the onset of a stroke. NTI also has the right to receive royalty payments from sales of Namenda(R) (memantine HCL), an approved drug marketed for Alzheimer's disease, and the right to receive payments from the development and marketing of XERECEPT(R) (corticorelin acetate injection), an investigational drug in Phase 3 clinical development for swelling associated with brain tumors. Additionally, NTI has rights to two compounds in early-stage development for Alzheimer's and Huntington's diseases.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
2. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
3. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
4. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. Neurobiological Technologies Sets Date for Second Quarter Financial Results
8. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Neurobiological Technologies Sets Date for Research and Development Day
11. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... detection of foodborne pathogens today announced the appointment of Mary ... Thomas , the Company,s President and CEO since 2009, who will ... The changes are effective today. In addition, Ms. Duseau ... ...
(Date:1/17/2017)... Research and Markets has announced the addition of Jain ... Companies" to their offering. ... The number of companies involved ... years. More than 1,000 companies have been identified to be ... profiled in the report along with tabulation of 811 collaborations. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Pono Ola , a ... healthy lifestyle, announced today the official launch of its much-anticipated Pono Board: a re-invented ... , In development for over a year, the patented Pono Board is the ...
(Date:1/17/2017)... 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... initiated a global Phase 2b induction study in ... targets alpha4beta7 integrin. The aim of this randomized, ... the safety/tolerability and efficacy of PTG-100 in approximately ... severe active disease. "We are ...
Breaking Biology Technology:
(Date:12/22/2016)... , December 22, 2016 SuperCom ... of secure solutions for the e-Government, Public Safety, HealthCare, and Finance ... of SuperCom, has been selected to implement and deploy a community-based ... Northern California , further expanding its presence in ... This ...
(Date:12/16/2016)... 2016 Research and Markets has announced the ... Forecast to 2021" report to their offering. ... The biometric vehicle access system ... CAGR of 14.06% from 2016 to 2021. The market is estimated ... reach 854.8 Million by 2021. The growth of the biometric vehicle ...
(Date:12/15/2016)... Advancements in biometrics will radically ... wellbeing (HWW), and security of vehicles by ... vehicles begin to feature fingerprint recognition, iris ... monitoring, brain wave monitoring, stress detection, fatigue ... detection. These will be driven by built-in, ...
Breaking Biology News(10 mins):